martes, 17 de noviembre de 2026
Oncology News: LUGPA 2026 - Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC (+...)
Oncology News
LUGPA 2026
Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC
Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer.
Medscape Medical News, November 17, 2026
https://www.medscape.com/index/list_13474_0
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario